SdJ17coZswmGYZzG+wtLvOc5/SnxkAAACMiFI68RfV5kONW480rhE2LnVsnP+nesZO9aSfVeN+//Y3N7jwh3cC/VBSPJ
3Tzoq21cP/nuKr7oRS9aPP//qxVGCSKwEkWz/2lmiKcSs/HTuNS19y8Xe3zY+yeJMtqeluHnigwx9fAWxMYmgDyauYD1o2ENBu
OAMBHkoSu3v6ruXG1SShifIgSeHB/o1o5zL14c7yWPB+dgw/npSxD8a4AI6vX4p7KD8cc+/PZPeyk3mT+34S0SSHjx8miYwvO545
AIUfbJ/+f4fkf8Km2Qf8/bf9+P8A61GyD/n7b/vx/wDWpXj2/D/gBaXf8f8AgkP2yf8A5/h+R/wo+2T/APP8PyP+FTbIP+ftv+/H
【ASCO-GU 2019】mCRPC一线治疗,恩杂鲁胺联合多西他赛优于多西他赛单药?肿瘤资讯 昨天编译:肿瘤资讯来源:肿瘤资讯转自:良医汇-肿瘤医生APP2019年2月14日—16日,美国
8jKz+zyVimH/PqTA7VVXxyam4sy5tVYICMxkxgYgGBwu3cc/4NSvTVBkkK7VpXcIUMwbddiToiHt3cQO
2LVx8c2t7SybXuWHj+tN+OcULXAMd0XD799v80EvqH3EY++vfu2b9/+23vu3bNnj2s7AGBAKc10dO7bt2/c0cc0NTUl+j7nytl